Users Stopping Anti-Obesity Jabs Put On Weight Far More Rapidly Compared to People Using Diet and Exercise
Fresh analysis indicates that individuals who come off popular GLP-1 drugs like Mounjaro or Wegovy may regain shed pounds much more quickly than those who end conventional lifestyle plans.
Published data in a prominent health publication demonstrates that while obese people frequently drop a large proportion of their body weight while on the medication, the mass is regained at an estimated rate of nearly a kilo each month after stopping.
"People purchasing these drugs need to be informed of the potential of rapid rebound weight gain when the medication concludes," warns expert Dr. Susan Jebb.
Such speed of recovery means a return to original mass in about 18 months.
Weighing Approaches
The study, which looked at 37 of studies involving over 9,000 of patients, contrasted the effects of these new drugs with other pills.
Researchers emphasize that individuals who shed pounds through dieting generally have a slower weight regain—approximately 0.1 kg a month—after stopping.
The Reason for the Fast Rebound
Doctors suggest the mechanism of the drugs accounts for the heightened regain.
These medications copy a body's own chemical called GLP-1, which controls appetite.
"Sustained high doses of GLP-1 concentrations far above than normal might result in the body to produce less of its own natural hormone, and could lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this medication leads to hunger is no longer kept in check, making overeating a significant risk."
A Chronic Disease?
Medical guidelines suggest the jabs for individuals with obesity-related health risks, alongside prescribed diet and exercise modifications.
Many experts contend that, due to the likelihood of relapse, the therapy should be considered life-long.
This perspective is reinforced by pharmaceutical companies, who say that the results "underscore the chronic character of obesity," comparing it to managing diseases like high blood pressure.
Patient Experiences
People who have stopped the medication describe a intense return of appetite.
"I experienced something that goes on and I was suddenly ravenous," recalled a patient.
This difficulty is compounded if individuals have not adopted permanent lifestyle or habit modifications during therapy.
Growing Interest
Recent estimates suggest that millions of people in the UK have tried these injections in the past year, with interest being substantial.
- Use is higher among females than men.
- The middle-aged age group shows the greatest usage rates.
- Many access the drugs through private healthcare rather than the NHS.
In conclusion, clinicians emphasize that while these medications are powerful agents for weight loss, they are not a permanent solution and maintained weight loss hinges on combined behavioural support.
